Iams Wealth Management LLC Increases Stake in Novo Nordisk A/S $NVO

Iams Wealth Management LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 34.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 49,278 shares of the company’s stock after acquiring an additional 12,617 shares during the period. Novo Nordisk A/S makes up 1.1% of Iams Wealth Management LLC’s investment portfolio, making the stock its 24th largest holding. Iams Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,734,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. NewSquare Capital LLC increased its position in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. acquired a new stake in Novo Nordisk A/S in the second quarter valued at $37,000. State of Wyoming purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $38,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $39,000. Finally, Copeland Capital Management LLC grew its position in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after buying an additional 186 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval of the oral Wegovy pill gives Novo a first‑to‑market position in oral GLP‑1 obesity treatments, expanding addressable market and making the drug easier to prescribe/scale than injectables. Explainer: What Novo Nordisk’s weight-loss pill approval means
• Positive Sentiment: Novo plans a U.S. launch in early January and is targeting the cash‑pay market at an introductory price (~$149/month reported), which could accelerate uptake and revenue if demand matches expectations. Wegovy pill to test demand from consumers with cash
• Positive Sentiment: Market reaction: multiple outlets report a sharp pre‑market/early session rally and unusually large call‑option activity, signaling investor optimism and short‑term speculative interest. Shares pop after GLP-1 pill approval
• Neutral Sentiment: Analysts highlight that NVO trades at a depressed forward multiple (seekingalpha note), so the approval could meaningfully re‑rate the stock if commercial execution succeeds — but valuation upside depends on sustained share gains. Seeking Alpha: The real comeback starts now with the Wegovy pill
• Negative Sentiment: Competition and pricing pressure remain material risks — Eli Lilly is close behind with its own oral option and dominates prescriptions with injectables, so market share battles and price competition could limit upside. Lilly, Novo lock horns in India’s obesity drug race
• Negative Sentiment: Geographic/generic risks—lower‑cost generics and delayed filings in some markets (e.g., Canada/India) could pressure future volumes and margins in regional markets. Canadians face longer wait for copycat Ozempic

Novo Nordisk A/S Trading Up 1.9%

Shares of NVO stock opened at $52.61 on Thursday. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a market capitalization of $234.90 billion, a price-to-earnings ratio of 15.29 and a beta of 0.67. The firm has a 50-day moving average price of $49.47 and a 200 day moving average price of $57.12. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.